Withings launches Body Scan 2 ultra-premium scale in the US

Withings has officially released its Body Scan 2 scale for sale in the United States, marking the commercial availability of the company’s latest ultra-premium health monitoring device. Priced at $600, the scale is available to order directly through the firm’s website and includes a complimentary one-month trial of the Withings+ premium health service.

The launch follows regulatory approvals secured earlier this year, allowing the manufacturer to bring the device to the US market. First unveiled in January, the Body Scan 2 represents a significant upgrade from its predecessor, increasing the number of analysable biomarkers from 40 to 60. The company states that the device offers data quality comparable to clinical-grade DEXA scans, positioning it as a high-fidelity alternative for at-home body composition analysis.

Key technological additions include Impedance Cardiography (ICG), which monitors the heart’s capacity to pump blood to the organs. The device also utilises Bioimpedance Spectroscopy (BIS) to assess total body water, cellular age, active cell mass, and metabolic efficiency through low-level electrical currents.

While the manufacturer describes the monitoring capabilities as clinical-grade, the assertion that the scale’s data matches DEXA scans is based on company statements rather than independent verification. The long-term utility of metrics such as cellular age and metabolic efficiency remains a subject of ongoing discussion within the health technology sector.

The release of the Body Scan 2 underscores Withings’ strategy to target consumers seeking detailed health insights without visiting clinical settings. By bundling the hardware with a subscription service, the company aims to provide continuous monitoring and data tracking for users willing to pay a premium for advanced biometric analysis.